SLC15A1 and malignant colon neoplasm: The inhibition of these receptors may presumably be associated with rhabdomyolysis (hOTCN2), severe drug adverse reactions (ASBT), drug–drug interactions (hPEPT1 or P-gp), and colon cancer (ASBT).